Windtree Therapeutics (WINT)
(Delayed Data from NSDQ)
$10.00 USD
-1.80 (-15.25%)
Updated Aug 13, 2024 03:59 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Windtree Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 6 | 22 | 17 | 23 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 5 | 7 | 23 | 18 | 24 |
Net Property & Equipment | 0 | 0 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 25 | 28 | 48 | 93 | 93 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 32 | 38 | 75 | 113 | 119 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 0 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 3 | 4 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 0 | 2 |
Total Current Liabilities | 4 | 2 | 5 | 6 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 5 | 7 | 17 | 16 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 15 | 15 | 15 | 17 | 20 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 4 | 4 | 3 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 28 | 33 | 43 | 44 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 851 | 838 | 830 | 790 | 763 |
Retained Earnings | -845 | -825 | -785 | -718 | -685 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 3 | 3 | 3 | 3 | 3 |
Total Shareholder's Equity | 3 | 10 | 42 | 70 | 75 |
Total Liabilities & Shareholder's Equity | 32 | 38 | 75 | 113 | 119 |
Total Common Equity | 3 | 10 | 42 | 70 | 75 |
Shares Outstanding | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | 11.30 | 10.01 | 41.88 | 69.55 | 74.94 |
Fiscal Year End for Windtree Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 3 | 4 | 7 | 11 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 2 | 2 |
Total Current Assets | NA | 3 | 5 | 9 | 13 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 25 | 25 | 25 | 25 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 30 | 32 | 36 | 41 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 1 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 2 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 0 | 0 |
Total Current Liabilities | NA | 5 | 4 | 4 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 5 | 5 | 5 | 5 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 15 | 15 | 15 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 4 | 4 | 4 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 15 | 29 | 29 | 29 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 853 | 851 | 850 | 850 |
Retained Earnings | NA | -835 | -845 | -840 | -835 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 3 | 3 | 3 | 3 |
Total Shareholder's Equity | NA | 15 | 3 | 7 | 12 |
Total Liabilities & Shareholder's Equity | NA | 30 | 32 | 36 | 41 |
Total Common Equity | 0 | 15 | 3 | 7 | 12 |
Shares Outstanding | 0.50 | 0.50 | 0.30 | 0.20 | 0.20 |
Book Value Per Share | 0.00 | 30.84 | 11.30 | 37.40 | 58.00 |